stockportfolio.pro
Phathom Pharmaceuticals, Inc. (PHAT)
Healthcare · Biotechnology · NasdaqGS
Phathom Pharmaceuticals, Inc. revenue & earnings — last 8 fiscal years
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $682,000 | $55.25M | $175.11M |
| Gross profit | — | — | — | — | — | $515,000 | $47.28M | $152.51M |
| Net income | $-1.29M | $-255.13M | $-129.07M | $-143.88M | $-197.72M | $-201.59M | $-334.33M | $-221.25M |
| Net margin | — | — | — | — | — | -29558.9% | -605.1% | -126.3% |
Source: Phathom Pharmaceuticals, Inc. SEC filings (10-K).
Explore 8 years of Phathom Pharmaceuticals, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track PHAT in your portfolio →
Phathom Pharmaceuticals, Inc. financial history by metric
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Phathom Pharmaceuticals, Inc. — frequently asked questions
What is Phathom Pharmaceuticals, Inc.'s revenue?
Phathom Pharmaceuticals, Inc. (PHAT) reported revenue of $175.11M for fiscal year 2025, up 216.9% from the prior year, according to its SEC filings.
Is Phathom Pharmaceuticals, Inc. profitable?
No — PHAT reported a net loss of $-221.25M in fiscal 2025.
What is PHAT's P/E ratio?
Phathom Pharmaceuticals, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Phathom Pharmaceuticals, Inc. have?
As of fiscal year 2025, PHAT carried roughly $209.09M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Phathom Pharmaceuticals, Inc.'s gross margin?
PHAT's gross margin was 87.1% in fiscal 2025 — gross profit of $152.51M on revenue of $175.11M.
What is Phathom Pharmaceuticals, Inc.'s market cap?
Phathom Pharmaceuticals, Inc. (PHAT) has a market capitalization of about $823.08M, based on the latest data in our nightly-refreshed cache.
When does Phathom Pharmaceuticals, Inc.'s fiscal year end?
PHAT's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Phathom Pharmaceuticals, Inc.'s official SEC filings (10-K and 10-Q), covering 8 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.